Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 38 articles:
HTML format



Single Articles


    November 2022
  1. ZHANG Y, Cai H, Wu MH, Zhu DH, et al
    miR-3682-3p activated by c-Myc aggravates the migration and stemness in hepatocellular carcinoma cells by regulating PTEN/PI3K/AKT/beta-catenin signaling.
    Dig Dis. 2022 Nov 10. pii: 000527800. doi: 10.1159/000527800.
    PubMed     Abstract available


    October 2022
  2. WANG X, Zhang J, Luo F, Shen Y, et al
    Application of CircRNA Circ_0071662 in the diagnosis and prognosis of hepatocellular carcinoma and its response to radiotherapy.
    Dig Dis. 2022 Oct 24. pii: 000527696. doi: 10.1159/000527696.
    PubMed     Abstract available


  3. HONG C, Dong HZ, Li RN, Zhu HB, et al
    Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.
    Dig Dis. 2022 Oct 18. pii: 000527574. doi: 10.1159/000527574.
    PubMed     Abstract available


    May 2022
  4. CAO D, Liu H, Bai L, Tang H, et al
    EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
    Dig Dis. 2022 May 30. pii: 000525232. doi: 10.1159/000525232.
    PubMed     Abstract available


    April 2022
  5. OP DEN WINKEL M, Nagel D, Seidensticker M, De Toni EN, et al
    Development and external validation of the Munich Sorafenib Evaluation Score for hepatocellular carcinoma.
    Dig Dis. 2022 Apr 14. pii: 000524336. doi: 10.1159/000524336.
    PubMed     Abstract available


    March 2022
  6. INUKAI Y, Yamamoto K, Honda T, Ito T, et al
    Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma.
    Dig Dis. 2022 Mar 28. pii: 000524298. doi: 10.1159/000524298.
    PubMed     Abstract available


  7. SHI L, Zhang S
    Identification of subclasses of decompensated cirrhotic patients with acute kidney injury with different responses to fluid input.
    Dig Dis. 2022 Mar 17. pii: 000524028. doi: 10.1159/000524028.
    PubMed     Abstract available


    February 2022
  8. JAHN M, Raschidi L, Ozcurumez MK, Arzideh F, et al
    Comparison of Mortality Prediction Scores in Intermediate-Care Patients with Liver Cirrhosis at a German university transplant Center; a prospective study.
    Dig Dis. 2022 Feb 16. pii: 000522595. doi: 10.1159/000522595.
    PubMed     Abstract available


  9. YAN J, Deng M, Wang Y, Zhu M, et al
    Transjugular intrahepatic portosystemic shunt for portal vein cavernous transformation: a systematic review and single-arm meta-analysis.
    Dig Dis. 2022 Feb 7. pii: 000522313. doi: 10.1159/000522313.
    PubMed     Abstract available


    January 2022
  10. MIJAC D, Krstic MN, Markovic AP, Popovic DD, et al
    Abnormal Liver Blood Tests: Primary Care Approach.
    Dig Dis. 2022;40:215-222.
    PubMed     Abstract available


  11. SEHGAL R, Kaur N, Ramakrishna G, Trehanpati N, et al
    Immune Surveillance by Myeloid-Derived Suppressor Cells in Liver Diseases.
    Dig Dis. 2022;40:301-312.
    PubMed     Abstract available


  12. GISZAS B, Weber M, Heidel FH, Reuken PA, et al
    Recurrent Upper Gastrointestinal Bleeding from Isolated Gastric Varices as Primary Symptom of Myelofibrosis: A Case Report on Combining Interventional and Pharmacologic Treatment Options.
    Dig Dis. 2022;40:530-534.
    PubMed     Abstract available


  13. KALAL CR, Maiwall R, Choudhary A, Premkumar M, et al
    Mannitol Is Comparable to Hypertonic Saline for Raised Intracranial Pressure in Acute Liver Failure (MAHAL Study): A Randomized Controlled Trial.
    Dig Dis. 2022;40:607-615.
    PubMed     Abstract available


  14. LEMMER P, Selbach N, Baars T, Porsch-Ozcurumez M, et al
    Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm.
    Dig Dis. 2022;40:644-653.
    PubMed     Abstract available


  15. MASIOR L, Grat M
    Primary Nonfunction and Early Allograft Dysfunction after Liver Transplantation.
    Dig Dis. 2022;40:766-776.
    PubMed     Abstract available


  16. GARRIDO I, Magalhaes A, Lopes J, Macedo G, et al
    Trastuzumab Emtansine-Induced Nodular Regenerative Hyperplasia: Is Dose Reduction Enough as a Preventable Measure?
    Dig Dis. 2022;40:787-792.
    PubMed     Abstract available


  17. KAM LY, Huang DQ, Teng MLP, Takahashi H, et al
    Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis.
    Dig Dis. 2022;40:734-744.
    PubMed     Abstract available


    November 2021
  18. SHAO X, Uojima H, Arai T, Ogawa Y, et al
    The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency.
    Dig Dis. 2021 Nov 22. pii: 000521062. doi: 10.1159/000521062.
    PubMed     Abstract available


  19. CHEN LS, Lee SW, Yang SS, Tsai HJ, et al
    Advances in the era of direct-acting antivirals for hepatitis C in patients with unresectable hepatocellular carcinoma.
    Dig Dis. 2021 Nov 9. pii: 000520721. doi: 10.1159/000520721.
    PubMed     Abstract available


  20. DREWES R, Heinze C, Pech M, Powerski M, et al
    Apparent diffusion coefficient can predict therapy response of hepatocellular carcinoma to transcatheter arterial chemoembolization.
    Dig Dis. 2021 Nov 8. pii: 000520716. doi: 10.1159/000520716.
    PubMed     Abstract available


    October 2021
  21. REITER FP, Ben Khaled N, Ye L, Zhang C, et al
    Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State of the Art Review.
    Dig Dis. 2021 Oct 13. pii: 000520095. doi: 10.1159/000520095.
    PubMed    


    July 2021
  22. OSWALD L, Nakanishi H, Kurosaki M, Kirino S, et al
    Plasma renin activity predicts prognosis and liver disease-related events in liver cirrhosis patients with ascites treated by tolvaptan.
    Dig Dis. 2021 Jul 30. pii: 000518099. doi: 10.1159/000518099.
    PubMed    


  23. JUNGST C, Justinger C, Fischer J, Berg T, et al
    Common ABCB4 and ABCB11 genotypes are associated with idiopathic chronic cholestasis in adults.
    Dig Dis. 2021 Jul 6. pii: 000518203. doi: 10.1159/000518203.
    PubMed    


    June 2021
  24. OCAL O, Rossler D, Ricke J, Seidensticker M, et al
    Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma.
    Dig Dis. 2021 Jun 29. pii: 000518101. doi: 10.1159/000518101.
    PubMed    


  25. KUBOTA K, Uojima H, Shao X, Iwasaki S, et al
    Additional L-carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.
    Dig Dis. 2021 Jun 28. pii: 000518067. doi: 10.1159/000518067.
    PubMed    


  26. OP DEN WINKEL M, Nagel D, de la Torre Alaez MA, Hempe S, et al
    A simple prognostic scoring system for hepatocellular carcinoma treated with selective internal radiation therapy.
    Dig Dis. 2021 Jun 10. pii: 000517458. doi: 10.1159/000517458.
    PubMed    


    May 2021
  27. KRSTIC MN, Mijac D, Tomasevic RS, Lukic S, et al
    Abnormal liver blood tests: Hepatologist approach.
    Dig Dis. 2021 May 10. pii: 000517110. doi: 10.1159/000517110.
    PubMed    


    April 2021
  28. MEYER JJ, Dreyhaupt J, Schwerdel D, Ettrich TJ, et al
    Blood-based targeted metabolomics discriminate patients with alcoholic liver cirrhosis from those with non-cirrhotic liver damage: an explorative study.
    Dig Dis. 2021 Apr 16. pii: 000516488. doi: 10.1159/000516488.
    PubMed    


  29. MANZHALII E, Falalyeyeva TM, Moyseyenko VO, Weiskirchen R, et al
    Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor?
    Dig Dis. 2021 Apr 9. pii: 000516412. doi: 10.1159/000516412.
    PubMed     Abstract available


    January 2021
  30. WEBER S, Benesic A, Buchholtz ML, Rotter I, et al
    Antimitochondrial Rather than Antinuclear Antibodies Correlate with Severe Drug-Induced Liver Injury.
    Dig Dis. 2021;39:275-282.
    PubMed     Abstract available


  31. XU Y, Hu X, Li J, Dong R, et al
    An Improved Scoring System Based on Platelet-Albumin-Bilirubin in Predicting Posthepatectomy Liver Failure Outcomes.
    Dig Dis. 2021;39:258-265.
    PubMed     Abstract available


  32. WADA N, Uojima H, Satoh T, Okina S, et al
    Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
    Dig Dis. 2021;39:234-242.
    PubMed     Abstract available


  33. PARK J, Lee EY, Li J, Jun MJ, et al
    NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.
    Dig Dis. 2021;39:634-645.
    PubMed     Abstract available


  34. YAMAMOTO K, Ikeya T, Okuyama S, Fukuda K, et al
    Association between the Frequency of Daily Toothbrushing and Development of Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2021;39:646-652.
    PubMed     Abstract available


  35. FREITAS M, Macedo Silva V, Xavier S, Magalhaes J, et al
    Early Kidney Dysfunction in Metabolic-Associated Fatty Liver Disease: Is Transient Elastography Useful as a Screening Method?
    Dig Dis. 2021;39:653-662.
    PubMed     Abstract available


  36. ATTA S, Kamel M, Mansour W, Hussein T, et al
    Ascitic Fluid Cytokines in Chronic Liver Disease: A Possible Prognostic Tool.
    Dig Dis. 2021;39:534-539.
    PubMed     Abstract available


    November 2020
  37. SCHINDLER P, Masthoff M, Harders F, Schmidt H, et al
    EFFICACY OF 90Y-RADIOEMBOLIZATION IN METASTATIC COLORECTAL CANCER DEPENDING ON THE PRIMARY TUMOR SIDE.
    Dig Dis. 2020 Nov 3. pii: 000512744. doi: 10.1159/000512744.
    PubMed     Abstract available


    September 2020
  38. BARABAS L, Hritz I, Istvan G, Tulassay Z, et al
    The behavior of MMP-2, MMP-7, MMP-9 and their inhibitors TIMP-1, TIMP-2 in adenoma-colorectal cancer sequence.
    Dig Dis. 2020 Sep 22. pii: 000511765. doi: 10.1159/000511765.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: